Children with Down syndrome and ALL fare as well as others treated on DFCI ALL protocols

(Dana-Farber Cancer Institute) Despite an elevated risk of toxicity from chemotherapy, children with Down syndrome and acute lymphoblastic leukemia (ALL) did not experience higher rates of relapse or treatment-related mortality compared with other children treated on Dana-Farber Cancer Institute ALL Consortium Protocols.